Gyros AB announces license and development agreement with Fujirebio Inc, Japan


Gyros AB announced today that it has signed a non-exclusive license and development agreement with Fujirebio Inc. for diagnostic applications using Gyros’ proprietary Compact Disc technology.

Under the terms of the agreement, Fujirebio will investigate combining Gyros’ Compact Disc technology with its own chemiluminescence immunoassay platform, in order to develop a new system for diagnostic applications.

Jan Würtz, CEO & President of Gyros AB said; “Gyros has now reached an important milestone in its effort of commercialize its unique microfluidics technology for clinical diagnostic applications. Miniaturization and integration of immunoassays using Gyros’ Compact Disk format could give significant productivity gains compared to traditional ways of working.”

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.